Quantitative lymphocyte alterations are frequent in patients with cancer, and strongly impact
prognosis and survival. The development of cancers in immunosuppressed patients has …

Background The neutrophil to lymphocyte ratio (NLR) is known to be prognostic for patients
with advanced cancers treated with immune checkpoint inhibitors (ICI), but has generally …

Simple Summary Neutrophil-to-lymphocyte ratio (NLR) as a prognostic indicator of patients
treated with immunotherapy has been fully reported. However, the dynamics of NLR after …

Chemotherapy is still the backbone of systemic treatment in the majority of cancers.
However, immunotherapies, especially those based on checkpoint inhibition, are additional …

Introduction Systemic inflammation is associated with prognosis in solid tumors. The
neutrophil-to-lymphocyte ratio (NLR) is a marker for the general immune response to various …

Abstract Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit
for a wide range of cancer types. Because only a subset of patients experience clinical …

Clinical trials with immune checkpoint inhibitors have provided important insights into the
mode of action of anticancer immune therapies and potential mechanisms of immune …

Background Systemic inflammation plays a role in carcinogenesis and is related to overall
survival in patients with different cancer types, including those treated with immune …

Accumulating evidence suggests that a high tumour burden has a negative effect on
anticancer immunity. The concept of tumour burden, simply defined as the total amount of …

Abstract Interleukin-2 (IL-2) targets cells bearing IL-2 receptors and induces different
degrees of lymphocytosis. This study retrospectively evaluated whether lymphocytosis, in …